Symptomatische Therapie der Multiplen Sklerose

1.

Hemmer B, et al (2021) Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-SpektrumErkrankungen und MOG-IgG-assoziierten Erkrankungen, S2k-Leitlinie. Deutsche Gesellschaft für Neurologie. Accessed 31/08/2022 2021

2.

Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Maurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lunemann JD, Lutterotti A, Meuth SG, Meyding-Lamade U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F, Multiple Sclerosis Therapy Consensus G (2021) Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord 14:17562864211039648. https://doi.org/10.1177/17562864211039648CrossRefPubMedPubMedCentral

3.

Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Stangel M, Zipp F, Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Stangel M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung H-P, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink V, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F, Multiple Sklerose Therapie Konsensus G (2021) Kommentar der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) zur S2k-Leitlinie Multiple Sklerose. DGNeurologie 4(4):319–326. https://doi.org/10.1007/s42451-021-00353-3CrossRefPubMedCentral

4.

Tholen R, Henze T, Höthker S, Flachenecker P, Lamprecht S, Sailer M, Tallner A, Vaney C (2019) Bewegungstherapie zur Verbesserung der Mobilität von Patienten mit Multipler Sklerose: Konsensusfassung für die S2e-Leitlinie der DGNR in Zusammenarbeit mit Physio Deutschland – Deutscher Verband für Physiotherapie (ZVK) e. V. NR 25(1):3–40

5.

Sconza C, Negrini F, Di Matteo B, Borboni A, Boccia G, Petrikonis I, Stankevičius E, Casale R (2021) Robot-assisted gait training in patients with multiple sclerosis: a randomized controlled crossover trial. Ann Univ Mariae Curie Sklodowska [Med]. https://doi.org/10.3390/medicina57070713CrossRef

6.

Munari D, Fonte C, Varalta V, Battistuzzi E, Cassini S, Montagnoli AP, Gandolfi M, Modenese A, Filippetti M, Smania N, Picelli A (2020) Effects of robot-assisted gait training combined with virtual reality on motor and cognitive functions in patients with multiple sclerosis: A pilot, single-blind, randomized controlled trial. Restor Neurol Neurosci 38(2):151–164. https://doi.org/10.3233/rnn-190974CrossRefPubMed

7.

Straudi S, Manfredini F, Lamberti N, Martinuzzi C, Maietti E, Basaglia N (2020) Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): a randomized controlled trial. Mult Scler 26(6):716–724. https://doi.org/10.1177/1352458519833901CrossRefPubMed

8.

Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, Hupperts R, Linnebank M, Magdič J, Oreja-Guevara C, Pozzilli C, Salgado AV, Ziemssen T (2018) Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Ther Adv Neurol Disord 11:1756286418803248. https://doi.org/10.1177/1756286418803248CrossRefPubMedPubMedCentral

9.

Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR, Investigators MSF (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68(4):494–502. https://doi.org/10.1002/ana.22240CrossRefPubMed

10.

Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J (2019) Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, phase III ENHANCE trial of prolonged-release Fampridine. CNS Drugs 33(1):61–79. https://doi.org/10.1007/s40263-018-0586-5CrossRefPubMed

11.

Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL (2004) Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 10(5):589–595. https://doi.org/10.1191/1352458504ms1085oaCrossRefPubMed

12.

Patejdl R, Tesar S, Zettl UK (2014) Multiple Sklerose, Neuromyelitis optica und spastische Bewegungsstörungen: Spezifische Symptomkontrolle und Lebensqualität (Multiple Sclerosis, Neuromyelitis Optica and Spasticity: Control of Specific Symptoms and Quality of Life). Fortschr Neurol Psychiatr 82(07):373–385CrossRefPubMed

13.

Etoom M, Khraiwesh Y, Lena F, Hawamdeh M, Hawamdeh Z, Centonze D, Foti C (2018) Effectiveness of physiotherapy interventions on spasticity in people with multiple sclerosis: a systematic review and meta-analysis. Am J Phys Med Rehabil 97(11):793–807. https://doi.org/10.1097/phm.0000000000000970CrossRefPubMed

14.

Vermöhlen V, Schiller P, Schickendantz S, Drache M, Hussack S, Gerber-Grote A, Pöhlau D (2018) Hippotherapy for patients with multiple sclerosis: a multicenter randomized controlled trial (MS-HIPPO). Mult Scler 24(10):1375–1382. https://doi.org/10.1177/1352458517721354CrossRefPubMed

15.

Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sorensen P, Thompson AJ, Vermersch P, Gold R, Montalban X (2016) Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler 22(11):1386–1396. https://doi.org/10.1177/1352458516643600CrossRefPubMed

16.

Cutter NC, Scott DD, Johnson JC, Whiteneck G (2000) Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 81(2):164–169. https://doi.org/10.1016/s0003-9993(00)90135-7CrossRefPubMed

17.

Wade DT, Collin C, Stott C, Duncombe P (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16(6):707–714. https://doi.org/10.1177/1352458510367462CrossRefPubMed

18.

Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2017) Neues zur symptomatischen MS-Therapie: Teil 2 – Gangstörung und Spastik. Nervenarzt 88(12):1428–1434. https://doi.org/10.1007/s00115-017-0439-3CrossRefPubMed

19.

Hoffmann V, Kuhn W, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, Müller T (2006) Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients. Eur J Neurol 13(1):72–76. https://doi.org/10.1111/j.1468-1331.2006.01145.xCrossRefPubMed

20.

Hellwig K, Stein FJ, Przuntek H, Müller T (2004) Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms. BMC Neurol 4(1):18. https://doi.org/10.1186/1471-2377-4-18CrossRefPubMedPubMedCentral

21.

Kamin F, Rommer PS, Abu-Mugheisib M, Koehler W, Hoffmann F, Winkelmann A, Benecke R, Zettl UK (2015) Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity. Spinal Cord 53(2):109–113. https://doi.org/10.1038/sc.2014.155CrossRefPubMed

22.

Rommer PS, Kamin F, Abu-Mugheisib M, Koehler W, Hoffmann F, Winkelmann A, Benecke R, Zettl UK (2016) Long-term effects of repeated cycles of Intrathecal triamcinolone acetonide on spasticity in MS patients. CNS Neurosci Ther 22(1):74–79. https://doi.org/10.1111/cns.12474CrossRefPubMed

23.

Nelson DA, Landau WM (2001) Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports. J Neurol Neurosurg Psychiatry 70(4):433–443. https://doi.org/10.1136/jnnp.70.4.433CrossRefPubMedPubMedCentral

24.

Hoeflich A, Fitzner B, Walz C, Hecker M, Tuchscherer A, Bastian M, Brenmoehl J, Schröder I, Willenberg HS, Reincke M, Zettl UK (2020) Systemic effects by Intrathecal administration of triamcinolone acetonide in patients with multiple sclerosis. Front Endocrinol 11:574. https://doi.org/10.3389/fendo.2020.00574CrossRef

25.

Platz T (2019) S2k-Leitlinie: Therapie des spastischen Syndroms. DGNeurologie 2(4):258–279. https://doi.org/10.1007/s42451-019-0090-2CrossRef

26.

Makhoul K, Ahdab R, Riachi N, Chalah MA, Ayache SS (2020) Tremor in multiple sclerosis—an overview and future perspectives. Brain Sci. https://doi.org/10.3390/brainsci10100722CrossRefPubMedPubMedCentral

27.

Rinker JR 2nd, Salter AR, Walker H, Amara A, Meador W, Cutter GR (2015) Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey. BMJ Open 5(1):e6714. https://doi.org/10.1136/bmjopen-2014-006714CrossRefPubMedPubMedCentral

28.

Alusi SH, Worthington J, Glickman S, Bain PG (2001) A study of tremor in multiple sclerosis. Brain 124(Pt 4):720–730. https://doi.org/10.1093/brain/124.4.720CrossRefPubMed

29.

Alusi SH, Aziz TZ, Glickman S, Jahanshahi M, Stein JF, Bain PG (2001) Stereotactic lesional surgery for the treatment of tremor in multiple sclerosis: a prospective case-controlled study. Brain 124(Pt 8):1576–1589. https://doi.org/10.1093/brain/124.8.1576CrossRefPubMed

30.

Alusi SH, Macerollo A, MacKinnon CD, Rothwell JC, Bain PG (2021) Tremor and dysmetria in multiple sclerosis: a neurophysiological study. Tremor Other Hyperkinet Mov 11:30. https://doi.org/10.5334/tohm.598CrossRef

31.

Erdeo F, Yildiz İ, Uca AU, Altaş M (2022) Evaluation of upper extremity ataxia through image processing in individuals with multiple sclerosis. Arq Neuropsiquiatr 80(4):384–390. https://doi.org/10.1590/0004-282x-anp-2020-0587CrossRefPubMed

32.

Hervault M, Balto JM, Hubbard EA, Motl RW (2017) Reliability, precision, and clinically important change of the Nine-Hole Peg Test in individuals with multiple sclerosis. Int J Rehabil Res 40(1):91–93. https://doi.org/10.1097/mrr.0000000000000209CrossRefPubMed

33.

Solaro C, Grange E, Di Giovanni R, Cattaneo D, Bertoni R, Prosperini L, Messmer Uccelli M, Marengo D (2020) Nine Hole Peg Test asymmetry in refining upper limb assessment in multiple sclerosis. Mult Scler Relat Disord 45:102422. https://doi.org/10.1016/j.msard.2020.102422CrossRefPubMed

34.

Salcı Y, Fil A, Armutlu K, Yildiz FG, Kurne A, Aksoy S, Nurlu G, Karabudak R (2017) Effects of different exercise modalities on ataxia in multiple sclerosis patients: a randomized controlled study. Disabil Rehabil 39(26):2626–2632. https://doi.org/10.1080/09638288.2016.1236411CrossRefPubMed

35.

Scheidler AM, Kinnett-Hopkins D, Learmonth YC, Motl R, López-Ortiz C (2018) Targeted ballet program mitigates ataxia and improves balance in females with mild-to-moderate multiple sclerosis. PLoS ONE 13(10):e205382. https://doi.org/10.1371/journal.pone.0205382CrossRefPubMedPubMedCentral

36.

Mills RJ, Yap L, Young CA (2007) Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005029.pub2CrossRefPubMed

37.

Albrecht H, Schwecht M, Pöllmann W, Parag D, Erasmus LP, König N (1998) Lokale Eisapplikation in der Therapie der gliedkinetischen AtaxieKlinischer Nachweis positiver Behandlungseffekte bei Patienten mit multipler Sklerose. Nervenarzt 69(12):1066–1073. https://doi.org/10.1007/s001150050384CrossRefPubMed

38.

Feys P, Helsen W, Liu X, Mooren D, Albrecht H, Nuttin B, Ketelaer P (2005) Effects of peripheral cooling on intention tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry 76(3):373–379. https://doi.org/10.1136/jnnp.2004.044305CrossRefPubMedPubMedCentral

39.

Naderi F, Javadi SA, Motamedi M, Sahraian MA (2012) The efficacy of primidone in reducing severe cerebellar tremors in patients with multiple sclerosis. Clin Neuropharmacol 35(5):224–226. https://doi.org/10.1097/WNF.0b013e31826249bbCrossRefPubMed

40.

Schroeder A, Linker RA, Lukas C, Kraus PH, Gold R (2010) Successful treatment of cerebellar ataxia and tremor in multiple sclerosis with topiramate: a case report. Clin Neuropharmacol 33(6):317–318. https://doi.org/10.1097/WNF.0b013e3181f84a39CrossRefPubMed

41.

Brandmeir NJ, Murray A, Cheyuo C, Ferari C, Rezai AR (2020) Deep brain stimulation for multiple sclerosis tremor: a meta-analysis. Neuromodulation 23(4):463–468. https://doi.org/10.1111/ner.13063CrossRefPubMed

42.

Zali A, Khoshnood RJ, Motavaf M, Salimi A, Akhlaghdoust M, Safari S, Ghajarzadeh M, Mirmosayyeb O (2021) Deep brain stimulation for multiple sclerosis tremor: a systematic review and meta-analysis. Mult Scler Relat Disord 56:103256. https://doi.org/10.1016/j.msard.2021.103256CrossRefPubMed

43.

Costello F (2016) Vision disturbances in multiple sclerosis. Semin Neurol 36(2):185–195. https://doi.org/10.1055/s-0036-1579692CrossRefPubMed

44.

Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2018) Neues zur symptomatischen MS-Therapie: Teil 4 – Störungen der Sexualfunktion und der Augenbewegungen. Nervenarzt 89(2):193–197. https://doi.org/10.1007/s00115-017-0441-9CrossRefPubMed

45.

Starck M, Albrecht H, Pollmann W, Dieterich M, Straube A (2010) Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol 257(3):322–327. https://doi.org/10.1007/s00415-009-5309-xCrossRefPubMed

46.

Thurtell MJ, Joshi AC, Leone AC, Tomsak RL, Kosmorsky GS, Stahl JS, Leigh RJ (2010) Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol 67(5):676–680. https://doi.org/10.1002/ana.21991CrossRefPubMedPubMedCentral

47.

Dieterich M, Straube A, Brandt T, Paulus W, Büttner U (1991) The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus. J Neurol Neurosurg Psychiatry 54(7):627–632. https://doi.org/10.1136/jnnp.54.7.627CrossRefPubMedPubMedCentral

48.

Dogru-Huzmeli E, Duman T, Cakmak AI, Aksay U (2021) Can diplopia complaint be reduced by telerehabilitation in multiple sclerosis patient during the pandemic?: A case report. Neurol Sci 42(10):4387–4390. https://doi.org/10.1007/s10072-021-05194-2CrossRefPubMedPubMedCentral

49.

Thurtell MJ, Leigh RJ (2010) Therapy for nystagmus. J Neuroophthalmol 30(4):361–371. https://doi.org/10.1097/WNO.0b013e3181e7518fCrossRefPubMed

50.

Freiha J, Riachi N, Chalah MA, Zoghaib R, Ayache SS, Ahdab R (2020) Paroxysmal symptoms in multiple sclerosis—a review of the literature. J Clin Med. https://doi.org/10.3390/jcm9103100CrossRefPubMedPubMedCentral

51.

Fallata A, Salter A, Tyry T, Cutter GR, Marrie RA (2017) Trigeminal neuralgia commonly precedes the diagnosis of multiple sclerosis. Int J MS Care 19(5):240–246. https://doi.org/10.7224/1537-2073.2016-065CrossRefPubMedPubMedCentral

52.

Di Stefano G, Maarbjerg S, Truini A (2019) Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain 20(1):20. https://doi.org/10.1186/s10194-019-0969-0CrossRefPubMedPubMedCentral

53.

Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, Nurmikko T (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 17(9):1113–e1188. https://doi.org/10.1111/j.1468-1331.2010.02999.xCrossRefPubMed

54.

Zakrzewska JM, Wu J, Brathwaite TS (2018) A systematic review of the management of trigeminal neuralgia in patients with multiple sclerosis. World Neurosurg 111:291–306. https://doi.org/10.1016/j.wneu.2017.12.147CrossRefPubMed

55.

Berger I, Nayak N, Schuster J, Lee J, Stein S, Malhotra NR (2017) Microvascular decompression versus stereotactic radiosurgery for trigeminal neuralgia: a decision analysis. Cureus 9(1):e1000. https://doi.org/10.7759/cureus.1000CrossRefPubMedPubMedCentral

56.

Chin LS, Regine WF (2010) Principles and practice of stereotactic radiosurgery. Springer, New York

57.

Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, Gingold J, Goverover Y, Halper J, Harris C, Kostich L, Krupp L, Lathi E, LaRocca N, Thrower B, DeLuca J (2018) Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler 24(13):1665–1680. https://doi.org/10.1177/1352458518803785CrossRefPubMedPubMedCentral

58.

Rosti-Otajärvi E, Ruutiainen J, Huhtala H, Hämäläinen P (2014) Relationship between subjective and objective cognitive performance in multiple sclerosis. Acta Neurol Scand 130(5):319–327. https://doi.org/10.1111/ane.12238CrossRefPubMed

59.

Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2018) New aspects of symptomatic MS treatment: Part 6—cognitive dysfunction and rehabilitation. Nervenarzt 89(4):453–459. https://doi.org/10.1007/s00115-017-0443-7CrossRefPubMed

60.

Sokolov AA, Grivaz P, Bove R (2018) Cognitive deficits in multiple sclerosis: recent advances in treatment and neurorehabilitation. Curr Treat Options Neurol 20(12):53. https://doi.org/10.1007/s11940-018-0538-xCrossRefPubMed

61.

Solaro C, Gamberini G, Masuccio FG (2018) Depression in multiple sclerosis: epidemiology, aetiology, diagnosis and treatment. CNS Drugs 32(2):117–133. https://doi.org/10.1007/s40263-018-0489-5CrossRefPubMed

62.

Marrie RA, Walld R, Bolton JM, Sareen J, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN (2018) Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. Gen Hosp Psychiatry 53:65–72. https://doi.org/10.1016/j.genhosppsych.2018.06.001CrossRefPubMed

63.

Dalgas U, Stenager E, Sloth M, Stenager E (2015) The effect of exercise on depressive symptoms in multiple sclerosis based on a meta-analysis and critical review of the literature. Eur J Neurol 22(3):443–e434. https://doi.org/10.1111/ene.12576CrossRefPubMed

64.

Kluger BM, Krupp LB, Enoka RM (2013) Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurology 80(4):409–416. https://doi.org/10.1212/WNL.0b013e31827f07beCrossRefPubMedPubMedCentral

65.

Flachenecker P, Kümpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, Trenkwalder C, Toyka KV (2002) Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 8(6):523–526. https://doi.org/10.1191/1352458502ms839oaCrossRefPubMed

66.

Flachenecker P, Meissner H (2008) Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessment. Mult Scler 14(2):274–277. https://doi.org/10.1177/1352458507082480CrossRefPubMed

67.

Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, Lutterotti A, Müller A, Stephan KE (2019) Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry 90(6):642–651. https://doi.org/10.1136/jnnp-2018-320050CrossRefPubMed

68.

Razazian N, Kazeminia M, Moayedi H, Daneshkhah A, Shohaimi S, Mohammadi M, Jalali R, Salari N (2020) The impact of physical exercise on the fatigue symptoms in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurol 20(1):93. https://doi.org/10.1186/s12883-020-01654-yCrossRefPubMedPubMedCentral

69.

Wendebourg MJ, Heesen C, Finlayson M, Meyer B, Pöttgen J, Köpke S (2017) Patient education for people with multiple sclerosis-associated fatigue: a systematic review. PLoS ONE 12(3):e173025. https://doi.org/10.1371/journal.pone.0173025CrossRefPubMedPubMedCentral

70.

Pöttgen J, Moss-Morris R, Wendebourg JM, Feddersen L, Lau S, Köpke S, Meyer B, Friede T, Penner IK, Heesen C, Gold SM (2018) Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis. J Neurol Neurosurg Psychiatry 89(9):970–976. https://doi.org/10.1136/jnnp-2017-317463CrossRefPubMed

71.

Seddone S, Marturano M, Bientinesi R, Lucchini M, Bassi P, Mirabella M, Nociti V (2021) Lower urinary tract disorders in multiple sclerosis patients: prevalence, clinical features, and response to treatments. Neurourol Urodyn 40(6):1500–1508. https://doi.org/10.1002/nau.24687CrossRefPubMedPubMedCentral

72.

Wang G, Marrie RA, Fox RJ, Tyry T, Cofield SS, Cutter GR, Salter A (2018) Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis. Mult Scler Relat Disord 20:16–21. https://doi.org/10.1016/j.msard.2017.12.006CrossRefPubMed

73.

Domurath B, Flachenecker P, Henze T, Feneberg W, Brandt A, Kurze I, Kirschner-Hermanns R, Kaufmann A, Bremer J, Vonthien M, Ratering K, Schäfer C, Vance WN, Schmidt P (2021) Aktuelles zu neurogenen Dysfunktionen des unteren Harntraktes bei Multipler Sklerose. Nervenarzt 92(4):349–358. https://doi.org/10.1007/s00115-020-01046-0CrossRefPubMedPubMedCentral

74.

Haggiag S, Bolla G, Picconi O, Galgani S, Gasperini C (2017) Discrepancies between urinary symptoms assessment and objective bladder dysfunctions in multiple sclerosis. Multiple Scler Demyelinating Disord 2(1):11. https://doi.org/10.1186/s40893-017-0029-zCrossRef

75.

Haensch C-A et al (2020) Diagnostik und Therapie von neurogenen Blasenstörungen, S1-Leitlinie. www.dgn.org/leitlinien. Zugegriffen: 6. Sept. 2022

76.

Bemelmans BL, Hommes OR, Van Kerrebroeck PE, Lemmens WA, Doesburg WH, Debruyne FM (1991) Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis. J Urol 145(6):1219–1224. https://doi.org/10.1016/s0022-5347(17)38581-6CrossRefPubMed

77.

Tadayyon F, Etemadifar M, Bzeih H, Zargham M, Nouri-Mahdavi K, Akbari M, Tadayyon B (2012) Association of urodynamic findings in new onset multiple sclerosis with subsequent occurrence of urinary symptoms and acute episode of disease in females. J Res Med Sci 17(4):382–385PubMedPubMedCentral

78.

Lucio AC, Campos RM, Perissinotto MC, Miyaoka R, Damasceno BP, D’Ancona CA (2010) Pelvic floor muscle training in the treatment of lower urinary tract dysfunction in women with multiple sclerosis. Neurourol Urodyn 29(8):1410–1413. https://doi.org/10.1002/nau.20941CrossRefPubMed

79.

Bosma R, Wynia K, Havlikova E, De Keyser J, Middel B (2005) Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 112(1):1–5. https://doi.org/10.1111/j.1600-0404.2005.00431.xCrossRefPubMed

80.

Vahlensieck W, Bauer HW, Piechota H, Ludwig M, Wagenlehner F (2015) Rezidivierende Harnwegsinfektionen: Wie vermeiden und behandeln? Dtsch Arztebl Int 112(37):16

81.

Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM (2018) The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: therapy and prevention. Urol Int 100(3):271–278. https://doi.org/10.1159/000487645CrossRefPubMed

82.

Fowler CJ, Panicker JN, Drake M, Harris C, Harrison SC, Kirby M, Lucas M, Macleod N, Mangnall J, North A, Porter B, Reid S, Russell N, Watkiss K, Wells M (2009) A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J 85(1008):552–559. https://doi.org/10.1136/jnnp.2008.159178CrossRefPubMed

83.

Lin SD, Butler JE, Boswell-Ruys CL, Hoang P, Jarvis T, Gandevia SC, McCaughey EJ (2019) The frequency of bowel and bladder problems in multiple sclerosis and its relation to fatigue: a single centre experience. PLoS ONE 14(9):e222731. https://doi.org/10.1371/journal.pone.0222731CrossRefPubMedPubMedCentral

84.

Hinds JP, Eidelman BH, Wald A (1990) Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology 98(6):1538–1542. https://doi.org/10.1016/0016-5085(90)91087-mCrossRefPubMed

85.

Alvino B, Arianna F, Assunta B, Antonio C, Emanuele D, Giorgia M, Leonardo S, Daniele S, Renato D, Buscarinu MC, Massimiliano M, Crisafulli SG, Aurora Z, Gabri Nicoletti C, Marco S, Viola B, Francesco P, Marfia AG, Grazia S, Valentina S, Davide O, Giovanni S, Gioacchino T, Gallo A (2022) Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study. J Neurol 269(3):1610–1617. https://doi.org/10.1007/s00415-021-10737-wCrossRefPubMed

86.

Khan F, McPhail T, Brand C, Turner-Stokes L, Kilpatrick T (2006) Multiple sclerosis: disability profile and quality of life in an Australian community cohort. Int J Rehabil Res 29(2):87–96. https://doi.org/10.1097/01.mrr.0000194393.56772.62CrossRefPubMed

87.

Nusrat S, Gulick E, Levinthal D, Bielefeldt K (2012) Anorectal dysfunction in multiple sclerosis: a systematic review. ISRN Neurol 2012:376023. https://doi.org/10.5402/2012/376023CrossRefPubMedPubMedCentral

88.

Preziosi G, Gordon-Dixon A, Emmanuel A (2018) Neurogenic bowel dysfunction in patients with multiple sclerosis: prevalence, impact, and management strategies. Degener Neurol Neuromuscul Dis 8:79–90. https://doi.org/10.2147/DNND.S138835CrossRefPubMedPubMedCentral

89.

Andresen V, Becker G, Frieling T, Goebel-Stengel M, Gundling F, Herold A, Karaus M, Keller J, Kim M, Klose P, Krammer H, Kreis ME, Kuhlbusch-Zicklam R, Langhorst J, Layer P, Lenzen-Großimlinghaus R, Madisch A, Mönnikes H, Müller-Lissner S, Rubin D, Schemann M, Schwille-Kiuntke J, Stengel A, Storr M, van der Voort I, Voderholzer W, Wedel T, Wirz S, Witzigmann H, Pehl C (2022) Z Gastroenterol 60(10):1528–1572. https://doi.org/10.1055/a-1880-1928CrossRefPubMed

90.

Miget G, Tan E, Pericolini M, Chesnel C, Haddad R, Turmel N, Amarenco G, Hentzen C (2022) The Neurogenic Bowel Dysfunction score (NBD) is not suitable for patients with multiple sclerosis. Spinal Cord. https://doi.org/10.1038/s41393-022-00837-3CrossRefPubMed

91.

Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM (1997) Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord 12(6):946–951. https://doi.org/10.1002/mds.870120617CrossRefPubMed

92.

Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, Brunetti G, Pacchetti C (2007) Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord 22(9):1239–1244. https://doi.org/10.1002/mds.21243CrossRefPubMed

93.

Lyseng-Williamson KA (2018) Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use. Drugs Ther Perspect 34(7):300–310. https://doi.org/10.1007/s40267-018-0532-0CrossRefPubMedPubMedCentral

94.

Nelson AD, Camilleri M, Chirapongsathorn S, Vijayvargiya P, Valentin N, Shin A, Erwin PJ, Wang Z, Murad MH (2017) Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. Gut 66(9):1611–1622. https://doi.org/10.1136/gutjnl-2016-311835CrossRefPubMed

95.

Ali H, Pamarthy R, Sarfraz S (2021) Role of prucalopride in treating functional constipation and gastroparesis: a systemic review. Cureus 13(4):e14306. https://doi.org/10.7759/cureus.14306CrossRefPubMedPubMedCentral

96.

Bellini M, Gambaccini D, Bassotti G (2016) Prucalopride: For functional constipation only? Tech Coloproctol 20(7):433–436. https://doi.org/10.1007/s10151-016-1477-8CrossRefPubMed

97.

Christensen P, Krogh K, Buntzen S, Payandeh F, Laurberg S (2009) Long-term outcome and safety of transanal irrigation for constipation and fecal incontinence. Dis Colon Rectum 52(2):286–292. https://doi.org/10.1007/DCR.0b013e3181979341CrossRefPubMed

98.

Teng M, Miget G, Moutounaick M, Kervinio F, Charlanes A, Chesnel C, Breton FL, Amarenco G (2022) Transanal irrigation for neurogenic bowel dysfunction in multiple sclerosis: a retrospective study. J Neurogastroenterol Motil 28(2):320–326. https://doi.org/10.5056/jnm19040CrossRefPubMedPubMedCentral

99.

Passananti V, Wilton A, Preziosi G, Storrie JB, Emmanuel A (2016) Long-term efficacy and safety of transanal irrigation in multiple sclerosis. Neurogastroenterol Motil 28(9):1349–1355. https://doi.org/10.1111/nmo.12833CrossRefPubMed

100.

Preziosi G, Gosling J, Raeburn A, Storrie J, Panicker J, Emmanuel A (2012) Transanal irrigation for bowel symptoms in patients with multiple sclerosis. Dis Colon Rectum 55(10):1066–1073. https://doi.org/10.1097/DCR.0b013e3182653bd1CrossRefPubMed

101.

He CX, Li SS, Du KL, Liu SQ, Zhang B, Feng F, Zheng JY (2021) Mid-term efficacy of sacral nerve stimulation for the treatment of chronic constipation. Zhonghua Wei Chang Wai Ke Za Zhi 24(12):1073–1078. https://doi.org/10.3760/cma.j.cn441530-20210719-00288CrossRefPubMed

102.

Sadeghi Bahmani D, Motl RW (2021) Rate, burden, and treatment of sexual dysfunction in multiple sclerosis: the case for exercise training as a new treatment approach. Mult Scler Relat Disord 51:102878. https://doi.org/10.1016/j.msard.2021.102878CrossRefPubMed

103.

Tudor KI, Eames S, Haslam C, Chataway J, Liechti MD, Panicker JN (2018) Identifying barriers to help-seeking for sexual dysfunction in multiple sclerosis. J Neurol 265(12):2789–2802. https://doi.org/10.1007/s00415-018-9064-8CrossRefPubMed

104.

Previnaire JG, Lecourt G, Soler JM, Denys P (2014) Sexual disorders in men with multiple sclerosis: evaluation and management. Ann Phys Rehabil Med 57(5):329–336. https://doi.org/10.1016/j.rehab.2014.05.002CrossRefPubMed

105.

Bartnik P, Wielgos A, Kacperczyk J, Pisarz K, Szymusik I, Podlecka-Pietowska A, Zakrzewska-Pniewska B, Wielgos M (2017) Sexual dysfunction in female patients with relapsing-remitting multiple sclerosis. Brain Behav 7(6):e699. https://doi.org/10.1002/brb3.699CrossRefPubMedPubMedCentral

106.

Pottgen J, van de Vis W, van Nunen A, Rose A, Engelbrecht J, Pirard M, Lau S, Heesen C, Kopke S, Rehabilitation in Multiple Sclerosis Special Interest Group on P, Neuropsychology (2020) Psychobehavioral treatment options for sexual dysfunction in multiple sclerosis: a systematic review. Int J MS Care 22(6):276–284. https://doi.org/10.7224/1537-2073.2020-012CrossRefPubMedPubMedCentral

107.

Krakowsky Y, Grober ED (2018) A practical guide to female sexual dysfunction: an evidence-based review for physicians in Canada. Can Urol Assoc J 12(6):211–216. https://doi.org/10.5489/cuaj.4907CrossRefPubMedPubMedCentral

108.

Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K (2013) Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003382.pub3CrossRefPubMedPubMedCentral

109.

Hucker A, McCabe MP (2015) Incorporating mindfulness and chat groups into an online cognitive behavioral therapy for mixed female sexual problems. J Sex Res 52(6):627–639. https://doi.org/10.1080/00224499.2014.888388CrossRefPubMed

110.

Flachenecker P, Eichstädt K, Berger K, Ellenberger D, Friede T, Haas J, Kleinschnitz C, Pöhlau D, Rienhoff O, Stahmann A, Zettl UK (2020) Multiple sclerosis in Germany: updated analysis of the German MS Registry 2014–2018. Fortschr Neurol Psychiatr 88(7):e1. https://doi.org/10.1055/a-1248-5258CrossRefPubMed

111.

Dorstyn DS, Roberts RM, Murphy G, Haub R (2019) Employment and multiple sclerosis: a meta-analytic review of psychological correlates. J Health Psychol 24(1):38–51. https://doi.org/10.1177/1359105317691587CrossRefPubMed

112.

Kalron A, Rosenblum U, Frid L, Achiron A (2017) Pilates exercise training vs. physical therapy for improving walking and balance in people with multiple sclerosis: a randomized controlled trial. Clin Rehabil 31(3):319–328. https://doi.org/10.1177/0269215516637202CrossRefPubMed

113.

Hasanpour Dehkordi A (2016) Influence of yoga and aerobics exercise on fatigue, pain and psychosocial status in patients with multiple sclerosis: a randomized trial. J Sports Med Phys Fitness 56(11):1417–1422PubMed

114.

Young HJ, Mehta TS, Herman C, Wang F, Rimmer JH (2019) The effects of M2M and adapted yoga on physical and psychosocial outcomes in people with multiple sclerosis. Arch Phys Med Rehabil 100(3):391–400. https://doi.org/10.1016/j.apmr.2018.06.032CrossRefPubMed

115.

Quinn E, Hynes SM (2021) Occupational therapy interventions for multiple sclerosis: a scoping review. Scand J Occup Ther 28(5):399–414. https://doi.org/10.1080/11038128.2020.1786160CrossRefPubMed

116.

Heidler M (2008) Speech and language therapy in multiple sclerosis—Symptom-oriented and inverse symptom-oriented training of dysarthric, dysphagic, aphasic and cognitive impairments. Neurol Rehabil 14:117–126

117.

Maser I (2009) Diagnostics and therapy of language, speech and swallowing disorders in patients with multiple sclerosis. Neurol Rehabil 15:325–326

118.

Khan F, Amatya B (2017) Rehabilitation in multiple sclerosis: a systematic review of systematic reviews. Arch Phys Med Rehabil 98(2):353–367. https://doi.org/10.1016/j.apmr.2016.04.016CrossRefPubMed

119.

Boesen F, Nørgaard M, Trénel P, Rasmussen PV, Petersen T, Løvendahl B, Sørensen J (2018) Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial—The Danish MS Hospitals Rehabilitation Study. Mult Scler 24(3):340–349. https://doi.org/10.1177/1352458517735188CrossRefPubMed

Springer Medizin

Symptomatische Therapie der Multiplen Sklerose

Zusammenfassung

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Dauerbrenner Arztbewertungsportale

Gesundheitsbewusste und sportliche 51-jährige Frau mit Gangstörung und neurokognitiven Einschränkungen

Progrediente Gangstörung und kognitiver Abbau eines 81-jährigen Patienten

Blickparese, Gangstörung und Areflexie – Symptomtrias verrät Diagnose

Künstliche Ernährung bei schwerer Demenz: Mehr Unheil als Nutzen

Update Tremorleitlinie: Handlungsempfehlungen in Kurzfassung